echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Lizhu, Qilu the same day into the 5 billion antifellarous large varieties Pfizer's arch-rivals will be.

    Lizhu, Qilu the same day into the 5 billion antifellarous large varieties Pfizer's arch-rivals will be.

    • Last Update: 2020-10-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical network October 15th, October 14th, CDE official website data show that Lizhu, Qilu respectively declared the injection of Voliconazole 4 types of imitation listing applications, were accepted.
    voliconazole for the whole body with antifygal drug TOP1 varieties, leading Pfizer in the domestic generic drug under the constant impact of the market share of only 40%.
    Figure 1: Lizhu, Qilu declared the registration of voliconazole for injection Source: CDE official website Figure 2: 2019 Voliconazole's enterprise competition pattern Source: Minet China's public medical institutions terminal competition pattern Minet data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal antifellar drug market, Volicanto with more than 5 billion yuan of sales.
    In terms of dosage form, injections accounted for 55.59 percent, tablets for 37.43 percent and capsules for 6.98 percent, and Pfizer, the leader, has lost half of its market share since 2015, falling from 49.98 percent to 45.70 percent in 2019.
    figure 3: Currently obtained the injection of Voliconazole production approval of the enterprise source: one-click search currently obtained the injection of Voliconazole production approval of the enterprise in addition to Puqiang (Pfizer's company), there are Zhuhai Ebon Pharmaceuticals, Jincheng Hais Pharmaceuticals, Sichuan Meida Kang Huakang Pharmaceuticals and Lizhu Group Lizhu Pharmaceutical Factory, there is currently no enterprise evaluation.
    Lizhu this declaration of the big probability is the new specifications of products, in addition to Qilu new joined the war situation, Fu'an Pharmaceutical Group Yantai only Chu Pharmaceuticals on October 10 declared the four types of imitation listing applications have been accepted, and the current listing applications involving enterprises such as Wuhan Qirui Pharmaceuticals, Hainan Beite Pharmaceuticals and Nanjing Sonic Dongyuan Pharmaceuticals.
    source: MiNet database, CDE official website.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.